Advertisement

Osteoporosis International

, Volume 25, Issue 12, pp 2721–2728 | Cite as

Differences in persistency with teriparatide in patients with osteoporosis according to gender and health care provider

  • I. Kyvernitakis
  • K. Kostev
  • A. Kurth
  • U. S. Albert
  • P. Hadji
Original Article

Abstract

Summary

This analysis investigated the persistence of teriparatide for treatment of osteoporosis in 829 patients according to gender and health care provider treated with teriparatide. This study showed that female patients were less persistent than males and those patients treated in the practices of orthopedic surgeons were more treatment persistent than patients treated in general practitioner (GP) practices.

Introduction

The optimal persistency of teriparatide (TPTD) is of the upmost importance to ensure fracture risk reduction and pain relief. Data reporting on gender-specific or health care provider-dependent differences on health care provider-dependent persistence is currently lacking.

Methods

We analyzed a large dataset extracted from the Disease Analyzer database (IMS Health, Germany). Out of a dataset of 15 million patients, we identified patients with osteoporosis who received first-time teriparatide prescriptions from January 2005 to December 2012.

Results

All 829 patients (677 females and 152 males) were included in the study. The patients were treated by 214 general practitioners (GPs) and 143 orthopedic surgeons. After 18 months of follow-up, 39.5 % of the female and 34 % of the male patients discontinued their treatment (p = 0.0308). We found a significant difference in the discontinuation rate of patients treated by orthopedic surgeons (35.0 %) compared to patients treated by GPs (44.2 %) (p = 0.0445). Additionally, at the end of the 18 months of follow up, 39.4 % of female and 47.8 % of male patients were still on treatment. We found a highly significant decreased risk for treatment discontinuation in patients with fractures prior to treatment initiation compared to those without such fractures (hazard ratio (HR) 0.77; 95 % confidence interval (CI) 0.66–0.90). There was a significantly increased risk of treatment discontinuation for female patients (HR 1.38; 95 % CI 1.10–1.74) compared to male patients.

Conclusions

In conclusion, female patients presented higher discontinuation rates of TPTD compared to males. Patients treated in the practices of orthopedic surgeons were more persistent than patients treated in GP practices. TPTD persistence in patients with osteoporosis is higher than with antiresorptives but is still suboptimal and needs to be improved to ensure fracture risk reductions comparable to randomized controlled trial (RCT) results.

Keywords

Compliance Fracture Osteoporosis Persistence Teriparatide 

Notes

Funding

None.

Conflicts of interest

PH received a speaker’s fee and educational and research funding from Amgen, Astra Zeneca, Elli Lilly, MSD, Novartis, Pfizer, P&G, and Roche. IK, AK, and USA have no conflicts of interest to declare. KK is the employer of IMS with no further conflicts of interest.

References

  1. 1.
    Pfeilschifter J, German Specialist Organisation for O (2006) DVO-guideline for prevention, diagnosis, and therapy of osteoporosis for women after menopause, for men after age 60 executive summary guidelines. Exp Clin Endocrinol Diab: Off J German Soc Endocrinol German Diab Assoc 114(10):611–22Google Scholar
  2. 2.
    Hadji P, Klein S, Gothe H, Haussler B, Kless T, Schmidt T et al (2013) The epidemiology of osteoporosis—Bone Evaluation Study (BEST): an analysis of routine health insurance data. Deutsches Arzteblatt Int 110(4):52–7Google Scholar
  3. 3.
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY et al (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344(19):1434–41PubMedCrossRefGoogle Scholar
  4. 4.
    Gallagher JC, Genant HK, Crans GG, Vargas SJ, Krege JH (2005) Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin Endocrinol Metab 90(3):1583–7PubMedCrossRefGoogle Scholar
  5. 5.
    Hadji P, Blettner M, Harbeck N, Jackisch C, Luck HJ, Windemuth-Kieselbach C et al (2013) The Patient’s Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer. Ann Oncol: Off J Eur Soc Med Oncol/ESMO 24(6):1505–12CrossRefGoogle Scholar
  6. 6.
    Hadji P, Jackisch C, Bolten W, Blettner M, Hindenburg HJ, Klein P et al (2014) Compliance and arthralgia in clinical therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy. Ann Oncol: Off J Eur Soc Med Oncol/ESMO 25(2):372–7CrossRefGoogle Scholar
  7. 7.
    Seeman E, Compston J, Adachi J, Brandi ML, Cooper C, Dawson-Hughes B (2007) Non-compliance: the Achilles’ heel of anti-fracture efficacy. Osteoporos Int: J Established Result Cooperation between Eur Found Osteoporos Natl Osteoporos Found USA 18(6):711–9CrossRefGoogle Scholar
  8. 8.
    Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T (2012) GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int: J Established Result Cooperation between Eur Found Osteoporos Natl Osteoporos Found USA 23(1):223–31CrossRefGoogle Scholar
  9. 9.
    Andrade SE, Kahler KH, Frech F, Chan KA (2006) Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 15(8):565–74, discussion 75–7PubMedCrossRefGoogle Scholar
  10. 10.
    Arden NK, Earl S, Fisher DJ, Cooper C, Carruthers S, Goater M (2006) Persistence with teriparatide in patients with osteoporosis: the UK experience. Osteoporos Int: J Established Result Cooperation between Eur Found Osteoporos Natl Osteoporos Found USA 17(11):1626–9CrossRefGoogle Scholar
  11. 11.
    Ziller V, Zimmermann SP, Kalder M, Ziller M, Seker-Pektas B, Hellmeyer L et al (2010) Adherence and persistence in patients with severe osteoporosis treated with teriparatide. Curr Med Res Opin 26(3):675–81PubMedCrossRefGoogle Scholar
  12. 12.
    Yu S, Burge RT, Foster SA, Gelwicks S, Meadows ES (2012) The impact of teriparatide adherence and persistence on fracture outcomes. Osteoporos Int: J Established Result Cooperation between Eur Found Osteoporos Natl Osteoporos Found USA 23(3):1103–13CrossRefGoogle Scholar
  13. 13.
    Becher H, Kostev K, Schroder-Bernhardi D (2009) Validity and representativeness of the “Disease Analyzer” patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Ther 47(10):617–26PubMedCrossRefGoogle Scholar
  14. 14.
    Ziller V, Kostev K, Kyvernitakis I, Boeckhoff J, Hadji P (2012) Persistence and compliance of medications used in the treatment of osteoporosis—analysis using a large scale, representative, longitudinal German database. Int J Clin Pharmacol Ther 50(5):315–22PubMedCrossRefGoogle Scholar
  15. 15.
    Motheral B, Brooks J, Clark MA, Crown WH, Davey P, Hutchins D et al (2003) A checklist for retrospective database studies—report of the ISPOR Task Force on retrospective databases. Value Health: J Int Soc Pharmacoecon Outcomes Res 6(2):90–7CrossRefGoogle Scholar
  16. 16.
    Foster SA, Foley KA, Meadows ES, Johnston JA, Wang SS, Pohl GM (2011) Adherence and persistence with teriparatide among patients with commercial, Medicare, and Medicaid insurance. Osteoporos Int: J Established Result Cooperation between Eur Found Osteoporos Natl Osteoporos Found USA 22(2):551–7CrossRefGoogle Scholar
  17. 17.
    Adachi JD, Hanley DA, Lorraine JK, Yu M (2007) Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study. Clin Ther 29(9):2055–67PubMedCrossRefGoogle Scholar
  18. 18.
    Hadji P, Ziller V, Kyvernitakis J, Bauer M, Haas G, Schmidt N et al (2013) Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis. Breast Cancer Res Treat 138(1):185–91PubMedCrossRefGoogle Scholar
  19. 19.
    Hazel-Fernandez L, Louder AM, Foster SA, Uribe CL, Burge RT (2013) Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare part D recipients: a retrospective cohort study. BMC Musculoskelet Disord 14:4PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Hadji P, Kyvernitakis J, Albert U, Jockwig J, Kostev K (2014) Gender differences in persistency to bisphosphonates in patients with metastatic breast and prostate cancer. Int J Clin Pharmacol Ther 52(5):352–9PubMedCrossRefGoogle Scholar
  21. 21.
    Kyvernitakis I, Saeger U, Ziller V, Bauer T, Seker-Pektas B, Hadji P (2013) The effect of age, sex hormones, and bone turnover markers on calcaneal quantitative ultrasonometry in healthy German men. J Clin Densitom: Off J Int Soc Clin Densitom 16(3):320–8CrossRefGoogle Scholar
  22. 22.
    Kyvernitakis I, Ziller V, Hars O, Bauer M, Kalder M, Hadji P (2014) Prevalence of menopausal symptoms and their influence on adherence in women with breast cancer. Climacteric: J Int Menopause Soc 17(3):252–9Google Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2014

Authors and Affiliations

  • I. Kyvernitakis
    • 1
  • K. Kostev
    • 1
    • 2
    • 3
  • A. Kurth
    • 4
  • U. S. Albert
    • 5
  • P. Hadji
    • 6
  1. 1.Department of Endocrinology, Reproductive Medicine and OsteoporosisPhilipps-University of MarburgMarburgGermany
  2. 2.Health & Social FacultyFresenius University of Applied SciencesIdsteinGermany
  3. 3.IMS HealthFrankfurtGermany
  4. 4.Department of Orthopaedic SurgeryFachkrankenhaus RatingenRatingenGermany
  5. 5.Department of Obstetrics and GynecologyKrankenhaus NordwestFrankfurtGermany
  6. 6.Department of Bone Oncology, Gynecological Endocrinology and Reproductive MedicineKrankenhaus NordwestFrankfurtGermany

Personalised recommendations